Time-release formulations are associated with the added advantages of convenience of dosing, improved compliance, and less fluctuation in blood levels across the course of the day.

$BCRX In both the SAD and the MAD studies, oral BCX9250 was safe and well tolerated, with no serious adverse events, No safety signals were seen.

Nice and consistent for the median patient FYI the poster this chart is from notes that none of these patients are from the clinical trial

$BCRX so they hit their Q4 numbers, had stellar phase IA results and guided for a 70Mil increase in revenue in 202e.

$BCRX it’s a great time to be a BioCryst shareholder, oooup FDA clinical pause, hey we still have 9250, fda clinical lift, 9250 is too tough, 9930 is too tough…

A trial involving 450 children in Burkina Faso found that three doses of the vaccine, plus a booster shot, were up to 80 percent effective at preventing infection.

BCX10013 pre clinical may be impressive

$BCRX GSK: ANNOUNCES POSITIVE PHASE IIA STUDY RESULTS FOR A NEW FIRST-IN-CLASS CANDIDATE MEDICINE FOR PATIENTS WITH TUBERCULOSIS * GSK - TREATMENT WAS GENERALLY WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS IDENTIFIED

$BCRX $ATNM $ATNM positive Phase 3 for AML and only 24 million float!!

Management revenue growth product execution Great research team market competitiveness against it's competition size and future growth of market clinical trials BCRX is a 10 on all fronts

it means you are already in that phase, you gonna enjoy of the Ocean view this year, from top of the penthouse, while sipping the Cappuccino (with some sweet cream on top).

2- the formulation process for this drug is easier than Mercks and if we keep up at this pace we will see the drug going to phase one in 2 months time ( since it is almost at mid point right now ).

$XERS Beautiful Phase 1 results.

$KPRX they have 4 clinical eye products one of which is promising in third stage this summer to fall and another in 2nd stage which they are very good at these

$KPRX News just getting out on positive Phase 1.

$KPRX Bouncing off bottom on positive Phase 1 data news.

$KPRX Added on positive Phase 1.

"EARLY IN STUDY, PATIENT FEEDBACK SUPPORTS IMPROVEMENT IN VISION"!!!!!!

$KPRX $ATXI Kiora Pharmaceuticals Phase 1 Human trials successful, NASDAQ compliance sorted, super low float which mean this is a very promising and volatile stock.

but also had performed previous studies on animals and results were absolutely astounding.

677K Float announced yesterday Phase 1 trial results for KIO-100; Results showed that a single intravitreal injection of KIO-100 decreased intraoculor inflammation in a dose dependent fashion, IMPROVED VISUAL ACUITY SIGNIFICANTLY.

677K Float announced yesterday Phase 1 trial results for KIO-100; Results showed that a single intravitreal injection of KIO-100 decreased intraoculor inflammation in a dose dependent fashion, IMPROVED VISUAL ACUITY SIGNIFICANTLY.

Promising study results.